Natixis Bicycle Therapeutics PLC Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Natixis holds 2,735 shares of BCYC stock, worth $35,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,735
Previous 2,882
5.1%
Holding current value
$35,500
Previous $58,000
6.9%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BCYC
# of Institutions
113Shares Held
40.8MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$122 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$46.1 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$30.4 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$29.2 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$25.4 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $385M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...